TABLE 2.
| Parameter | Value |
|---|---|
| ICU admissions | |
| At least one ICU admission during hospitalization | 177 (42.5) |
| Patients with >1 ICU admission during hospitalization | 43 (10.3) |
| In ICU at index culture collection | 112 (26.9) |
| ICU length of stay (days) | 14 (7, 32) |
| Mechanical ventilation for ≥48 h prior to index positive culture | 68 (16.3) |
| Duration of mechanical ventilation (days) | 22.5 (12, 36) |
| Culture information | |
| Hospital-acquired infection b | 206 (49.5) |
| Culture specimen | |
| Respiratory culture specimen | 103 (24.8) |
| Aspirate | 20 (4.8) |
| Bronchoalveolar lavage | 15 (3.6) |
| Sputum | 68 (16.3) |
| Wound | 87 (20.9) |
| Blood | 81 (19.5) |
| Fluid | 57 (13.7) |
| Tissue | 53 (12.7) |
| Urine | 17 (4.1) |
| Fecal | 13 (3.1) |
| Bone | 8 (1.9) |
| Catheter tip | 2 (0.5) |
| Concomitant bacteremia | 8 (1.9) |
| ID consult | 380 (91.3) |
| Surgery consult | 214 (51.4) |
| Surgical intervention c | 219 (52.6) |
| Active therapy before ERV d | 196 (47.1) |
| Aminoglycoside | 22 (11.2) |
| Carbapenem | 58 (29.6) |
| Cefepime | 44 (10.6) |
| Ceftazidime-avibactam | 16 (3.8) |
| Ceftolozane-tazobactam | 2 (0.5) |
| Meropenem-vaborbactam | 3 (0.7) |
| Polymyxins | 2 (1) |
| Quinolone | 11 (5.6) |
| Tigecycline | 8 (1.9) |
| Trimethoprim/sulfamethoxazole | 10 (2.4) |
| Daptomycin | 23 (5.5) |
| Linezolid/tedizolid | 25 (12.8) |
| Vancomycin | 70 (16.8) |
| Other | 72 (36.7) |
| ERV treatment specifics | |
| Rationale for ERV use | |
| Consolidation of regimen | 165 (39.7) |
| Lack of oral access | 16 (3.8) |
| Double CRE coverage | 31 (7.5) |
| ERV regimens | |
| Dose | |
| 1 mg/kg | 403 (96.9) |
| 1.5 mg/kg | 13 (3.1) |
| Frequency | |
| Every 12 h | 395 (95) |
| Every 12 h on day 1, then every 24 h | 14 (3.3) |
| Every 24 h | 7 (1.7) |
| ERV duration of therapy | 6.9 (4.1, 11.9) |
| Concomitant therapy e | 211 (50.7) |
| Amikacin | 18 (4.3) |
| Aztreonam | 2 (0.5) |
| Ciprofloxacin | 5 (1.2) |
| Colistin | 5 (1.2) |
| Ertapenem | 2 (0.5) |
| Gentamicin | 1 (0.2) |
| Imipenem | 5 (1.2) |
| Levofloxacin | 7 (1.7) |
| Meropenem | 37 (8.9) |
| Polymyxin B | 6 (1.4) |
| TMP/SMX | 9 (2.2) |
| Tobramycin | 9 (2.2) |
| Other | 111 (26.7) |
| Discharge disposition | |
| Home | 154 (37) |
| LTAC | 108 (26) |
| Rehab center | 35 (8.4) |
| Outside hospital | 1 (0.2) |
| Hospice | 28 (6.7) |
| Morgue | 82 (19.7) |
| Hospital length of stay (days) | 21 (11, 41) |
Data presented as number (%) or median (IQR), as appropriate.
Hospital-acquired infection: Index positive culture collected ≥48 h from hospital admission (includes time accrued at previous institution if the patient transferred from an outside hospital).
Surgical intervention: Incision and drainage (n = 68), debridement (n = 51), amputation (n = 10), valvular replacement (n = 2), invasive device removal (n = 6), other (n = 82).
Total may exceed n of 416 due to receipt of multiple antibiotics.
Active therapy: Demonstrated in vitro susceptibility.
Concomitant therapy: Antibiotic administered for ≥48 continuous hours while the patient received eravacycline.
ICU, intensive care units; ID, infectious diseases; ERV, eravacycline; CRE, carbapenem-resistant Enterobacterales; LTAC, long-term acute care.